Michael Caligiuri - Innate Pharma Member of the Supervisory Board
| IPH Stock | EUR 2.24 0.02 0.88% |
Executive
Dr. Michael Caligiuri is Member of the Supervisory Board of Innate Pharma SA. He is also Chief Executive Officer of the James Cancer Hospital and Director of the Comprehensive Cancer Center at the Ohio State University. since 2013.
| Age | 57 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 33 4 30 30 30 30 |
| Web | https://www.innate-pharma.com |
Innate Pharma Management Efficiency
The company has return on total asset (ROA) of (0.043) % which means that it has lost $0.043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1731) %, meaning that it generated substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | EXECUTIVE Age | ||
| Florence Sejourne | Genfit | N/A | |
| Frederic Desdouits | Genfit | N/A | |
| MarieBleuenn Terrier | Cellectis | 41 | |
| Philippe Moons | Genfit | N/A | |
| Philippe Duchateau | Cellectis | 60 | |
| Stephan Reynier | Cellectis | N/A | |
Management Performance
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 |
Innate Pharma Leadership Team
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Butler, Executive Vice President General Manager, US | ||
| Odile Belzunce, VP Operations | ||
| Eric Vivier, Chief Scientific Officer | ||
| Jean Fourni, Founder | ||
| Irina StaatzGranzer, Vice Chairman and Independent Member of the Supervisory Board | ||
| DVM MBA, VP Founder | ||
| Frederic MBA, VP CFO | ||
| Mondher MD, Chairman CEO | ||
| Herve Brailly, Chairman of the Management Board, Member of the Executive Committee, CEO | ||
| Jerome Tiollier, Member of the Executive Board, Executive Vice President - Development | ||
| Karsten Knudsen, Member of the Supervisory Board - Representative of Novo Nordisk AG | ||
| Mondher Mahjoubi, Chairman of the Executive Board, CEO | ||
| Nicolai Wagtmann, Chief Scientific Officer, Executive VP and Member of Executive Board | ||
| JeanYves Blay, Member of the Supervisory Board | ||
| JeanCharles Soria, Member of the Supervisory Board | ||
| Gilles Brisson, Chairman and Independent Member of the Supervisory Board | ||
| LaureHelene Mercier, Director of Investor Relations | ||
| Marc Bonneville, Founder | ||
| Catherine Moukheibir, Member of the Executive Committee, Executive Vice President Member of the Management Board - Consultant Senior Finance Advisor | ||
| Patrick Langlois, Member of the Supervisory Board | ||
| Marcus Schindler, Member of the Supervisory Board, Representative of Novo Nordisk | ||
| Alessandro MD, Founder | ||
| Veronique Chabernaud, Member of the Supervisory Board | ||
| Marcel Rozencweig, Member of the Executive Committee, Executive Vice President | ||
| Michael Caligiuri, Member of the Supervisory Board | ||
| Pierre Dodion, Member of the Executive Committee, Chief Medical Officer | ||
| Mailys Ferrere, Member of the Supervisory Board | ||
| Yannis Morel, Member of the Executive Committee, Executive Vice President Business Development | ||
| Philippe Pouletty, Independent Member of the Supervisory Board | ||
| Franois Romagn, Founder |
Innate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innate Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Innate Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Innate Pharma's short interest history, or implied volatility extrapolated from Innate Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.Note that the Innate Pharma information on this page should be used as a complementary analysis to other Innate Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |